Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles
The Journal of Pharmacology and Experimental Therapeutics · 2023-04 · 385 (1) · 35-49
DOI: 10.1124/jpet.122.001384 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2023-04. Verfasst von Behnaz Lahooti und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas (B.L., R.G.A., D.P., S.S., T…. Hauptthemen laut MEDLINE: Endothelial Cells, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Existing vascular endothelial growth factor-oriented antiangiogenic approaches are known for their high potency. However, significant side effects associated with their use drive the need for novel antiangiogenic strategies. The small GTPase RhoA is an established regulator of actin cytoskeletal dynamics. Previous studies have highlighted the impact of endothelial RhoA pathway on angiogenesis. Rho-associate kinase (ROCK), a direct RhoA effector, is potently inhibited by Fasudil, a clinically relevant ROCK inhibitor. Here, we aimed to target the RhoA signaling in endothelial cells by generating Fasudil-encapsulated CD31-targeting liposomes as a potential antiangiogenic therapy. The liposomes presented desirable characteristics, preferential binding to CD31-expressing HEK293T cells and to endothelial cells, inhibited stress fiber formation and cytoskeletal-related morphometric parameters, and inhibited in vitro angiogenic functions. Overall, this work shows that the nanodelivery-mediated endothelial targeting of RhoA signaling can offer a promising strategy for angiogenesis inhibition in vascular-related diseases. SIGNIFICANCE STATEMENT: Systemic administration of antiangiogenic therapeutics induces side effects to non-targeted tissues. This study, among others, has shown the impact of the RhoA signaling in the endothelial cells and their angiogenic functions. Here, to minimize potential toxicity, this study generated CD31-targeting liposomes with encapsulated Fasudil, a clinically relevant Rho kinase inhibitor, and successfully targeted endothelial cells. In this proof-of-principle study, the efficient Fasudil delivery, its impact on the endothelial signaling, morphometric alterations, and angiogenic functions verify the benefits of site-targeted antiangiogenic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, Texas (B.L., R.G.A., D.P., S.S., T.J.A., U.B., A.A.-A., N.A.G., C.M.M.); Laboratory of Molecular Pharmac…
ORCID-Profile: Ulrich Bickel, Constantinos M Mikelis
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
Zitieren
APA
Lahooti, B., Akwii, R. G., Patel, D., ShahbaziNia, S., Lamprou, M., Madadi, M., Abbruscato, T. J., Astrinidis, A., Bickel, U., Al-Ahmad, A., German, N. A., Mattheolabakis, G., & Mikelis, C. M. (2023). Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles. The Journal of Pharmacology and Experimental Therapeutics, 385(1), 35-49. https://doi.org/10.1124/jpet.122.001384
Vancouver
Lahooti B, Akwii RG, Patel D, ShahbaziNia S, Lamprou M, Madadi M, et al. Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles. The Journal of Pharmacology and Experimental Therapeutics. 2023;385(1):35-49. doi:10.1124/jpet.122.001384
BibTeX
@article{Lahooti2023,
author = {Lahooti, Behnaz and Akwii, Racheal G and Patel, Dhavalkumar and ShahbaziNia, Siavash and Lamprou, Margarita and Madadi, Mahboubeh and Abbruscato, Thomas J and Astrinidis, Aristotelis and Bickel, Ulrich and Al-Ahmad, Abraham and German, Nadezhda A and Mattheolabakis, George and Mikelis, Constantinos M},
title = {Endothelial-Specific Targeting of RhoA Signaling via CD31 Antibody-Conjugated Nanoparticles},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2023},
volume = {385},
number = {1},
pages = {35--49},
doi = {10.1124/jpet.122.001384}
}
EUVIMED